Drug factory · FDA FEI 1510437
Patheon Pharmaceuticals Inc.
2110 E Galbraith Rd., Cincinnati, OH, United States
Problems found, fixed voluntarily at FDA's last inspection, Sep 26, 2025.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
15 drug inspections on record since 2010: 5 with no problems, 10 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Sep 26, 2025 | Problems found, fixed voluntarily | Drug Quality Assurance | 3 |
| Apr 21, 2023 | No problems found | Drug Quality Assurance | — |
| Jan 14, 2020 | No problems found | Drug Quality Assurance | — |
| Feb 14, 2018 | Problems found, fixed voluntarily | Drug Quality Assurance | 6 |
| Mar 2, 2017 | Problems found, fixed voluntarily | Drug Quality Assurance | 1 |
| Mar 11, 2016 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Oct 30, 2014 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jun 18, 2014 | No problems found | Drug Quality Assurance | — |
| Aug 26, 2013 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| May 13, 2013 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Aug 16, 2012 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jan 12, 2012 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Mar 24, 2011 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jan 31, 2011 | No problems found | Drug Quality Assurance | — |
| Mar 24, 2010 | No problems found | Drug Quality Assurance | — |
What inspectors wrote down
From FDA's Form 483 citations: conditions an investigator observed that may violate drug manufacturing rules, as FDA published them.
Sep 26, 2025 inspection
- Investigations of discrepancies, failures 21 CFR 211.192
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. - Procedures not in writing, fully followed 21 CFR 211.22(d)
The responsibilities and procedures applicable to the quality control unit are not fully followed. - Written procedures not established/followed 21 CFR 211.67(b)
Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Feb 14, 2018 inspection
- SOPs not followed / documented 21 CFR 211.100(b)
Written production and process control procedures are not followed in the execution of production and process control functions. - Extent of discrepancy, failure investigations 21 CFR 211.192
Investigations of an unexplained discrepancy did not extend to other batches of the same drug product. - Sanitation--buildings not clean, free of infestation 21 CFR 211.56(a)
Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition. - Buildings not maintained in good state of repair 21 CFR 211.58
Buildings used in the manufacturing, processing, packing and holding of a drug product are not maintained in a good state of repair. - Cleaning / Sanitizing / Maintenance 21 CFR 211.67(a)
Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. - Calibration/Inspection/Checking not done 21 CFR 211.68(a)
Routine calibration of automatic equipment is not performed according to a written program designed to assure proper performance.
Mar 2, 2017 inspection
- SOPs not followed / documented 21 CFR 211.100(b)
Written production and process control procedures are not followed in the execution of production and process control functions.
Registered with FDA for: analysis; api manufacture; label; manufacture; pack.